Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dia-Artem
- Development stage
- Phase 4
- Lead developer
- Obsons Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dia-Artem is an oral fixed-dose combination antimalarial suspension containing artemether and lumefantrine, developed by Obsons Pharmaceuticals. It is indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including multi-drug resistant strains. Artemether, a rapidly acting artemisinin derivative, is metabolized to dihydroartemisinin and works by generating toxic free radicals upon activation by heme iron, which alkylate and damage parasite proteins and lipids. It also inhibits the parasite's sarcoplasmic/endoplasmic reticulum calcium ATPase (PfATP6). Lumefantrine, a longer-acting synthetic fluorene derivative, prevents the detoxification of toxic free heme into non-toxic beta-hematin by complexing with hemin. Together, this combination provides rapid parasite clearance and prevents recrudescence.
- Brand names
- Dia-Artem
- Other names
- Dia-Artem Suspensionartemether + lumefantrine
02
Targets
ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)
Beyond the preview
Go deeper on Dia-Artem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dia-Artem.